Table 2.
Normal (%) | NTDs (%) | Other/blastopore closure defects (%) | |
---|---|---|---|
Uninjected/control MO (20 ng) | 47/47 (96) | 0/27 (0) | 0/27 (0) |
gpc5-MO (10 ng + 10 ng co-MO)** | 22/69 (32) | 44/69 (64) | 3/69 (4) |
Summary of three experiments (**P < 0.0001, chi-square)